Reaction
Needle Track Marks reporting signals
As of the last recalculation, Needle Track Marks appears in 402 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is NEMOLIZUMAB-ILTO (PRR 85.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nemolizumab-Ilto | 20 | 85.7 | 85.8 |
| Abaloparatide | 14 | 25.5 | 25.5 |
| Fremanezumab-Vfrm | 3 | 13.6 | 13.6 |
| Galcanezumab-Gnlm | 7 | 11.7 | 11.7 |